- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Total 4546 results
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingFirst-line Treatment of Advanced Pancreatic CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPostoperative Pain Of Laparoscopic Surgery
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingGastroscopic and Colonoscopic Sedation
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingImproved Glycemic Control in Patients With Type 2 Diabetes
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRecurrent Vulvovaginal CandidiasisChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingPatients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingA Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.Non-squamous Non-small-cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingClassical Hodgkin LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingNon-Small-Cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingTreatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Hepatocellular CarcinomaChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdTerminated
-
Jiangsu HengRui Medicine Co., Ltd.Terminated
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdCompletedBreast Cancer | Gastric CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedUsed to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)China
-
Jiangsu Rec-Biotechnology Co., Ltd.CompletedCOVID-19Russian Federation, Nepal
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced Solid TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMixed Hyperlipidemia | Non-familial HypercholesterolemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedDiabetes in AdultsChina
-
Jiangsu HengRui Medicine Co., Ltd.Withdrawn
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAdjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedER+ / HER2- Advanced Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdCompleted
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdCompletedTriple-negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed